Related Experiment Video
Updated: Sep 10, 2025

Dissection of the Auditory Bulla in Postnatal Mice: Isolation of the Middle Ear Bones and Histological Analysis
Published on: January 4, 2017
Middle ear myoclonus: pathophysiology and management
Amber Zhang-Kraczkowska1, Wai Keat Wong2
1Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
Middle ear myoclonus (MEM) causes tinnitus from involuntary muscle contractions. Treatments include medications, surgery, and emerging botulinum toxin therapies, requiring individualized patient approaches.
Area of Science:
- Otolaryngology
- Neurology
Background:
- Middle ear myoclonus (MEM) is a rare condition causing objective and subjective tinnitus.
- It involves involuntary contractions of the stapedius and/or tensor tympani muscles.
Purpose of the Study:
- To comprehensively analyze the pathophysiology and treatment of middle ear myoclonus.
- To review current and emerging therapeutic strategies for MEM.
Main Methods:
- Literature review of studies on middle ear myoclonus pathophysiology and treatment.
- Analysis of pharmacological, surgical, and emerging treatment options.
Main Results:
- Pharmacological options include clonazepam, carbamazepine, and piracetam.
- Surgical resection shows promise but carries risks; endoscopic techniques improve visualization.
- Botulinum toxin is an emerging, less invasive option, with intratympanic delivery showing early efficacy.
Conclusions:
- MEM is complex with variable presentations, necessitating a multidisciplinary approach.
- Pharmacological and surgical treatments are generally favorable, but botulinum toxin shows growing interest.
- Further research is needed to clarify mechanisms, improve diagnosis, and standardize treatment.
More Related Videos
09:07Author Spotlight: Advancing Endoscopic Ossiculoplasty – Techniques, Innovations, and Practical Guidance for Clinical Integration
Published on: January 26, 2024
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myocarditis III: Medical Management
The Auditory Ossicles
The aptly named stapes look very much like a stirrup. The three ossicles are unique to mammals, and each plays a role in...
Mitral Stenosis III: Medical Management
Tonsillitis II: Management
Pericarditis III: Medical Management